Pharma, R&D

Daiichi Sankyo faces FDA challenges on missing data, credibility and safety concerns in hunt for 2 new drug OKs

When Daiichi Sankyo’s team takes the floor at tomorrow’s scheduled meeting of the FDA's cancer drug experts, they can expect some hard questions from regulators about two new approvals they're pushing for in the oncology arena.

Picked up 8 years ago in the $805 million Plexxikon buyout, pexidartinib was in a Phase I dose escalation study at the time. Over the years, the kinase inhibitor gained a breakthrough drug designation on its way to a filing earlier this year for adult patients with benign tumors known as symptomatic tenosynovial giant cell tumor.

Currently, these cases are usually treated through surgery. But surgery isn't always possible.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->